Translational application of the SPHK2 pathway has the potential to have far reaching implications in the therapy of PA infection in CF patients by two mechanisms such as 1) Targeting the SPHK2 pathway mediated pathology and 2) Reducing the virulence of the organism by resisting its alteration of the host genome. Here, SPHK2 is linked to cystic fibrosis.